Abstract 1288P
Background
Neoadjuvant chemotherapy (CT) has limited benefit over surgery alone for resectable non-small cell lung cancer (NSCLC). Recent trials have shown promising results for combining immune checkpoint inhibitors with platinum-doublet chemotherapy (ICI plus CT).
Methods
We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) that compared neoadjuvant ICI plus CT versus CT alone in patients with resectable NSCLC. We searched PubMed, Scopus, and Cochrane Library databases, as well as the ASCO, ESMO, and AACR websites. We used a fixed effects model for analysis and assessed heterogeneity with I2 statistics.
Results
We included six RCTs with 2,471 patients, of whom 75% were male, 47% had non-squamous, and 53% had squamous cell carcinoma (SCC). The median age was 63.3 years (ranged from 29 to 88). After neoadjuvant therapy, 84% of patients in the ICI plus CT group underwent surgery compared to 81% in the CT group (p=0.16); R0 resection was reported in 78% versus 67% of patients (p<0.01), respectively. We found a significantly higher pathologic complete response (risk ratio [RR] 5.81 [95%CI 4.26-7.92]) and major pathologic response (RR 3.57 [3.09-4.55]) in patients who received ICI plus CT than those in the CT group. Treatment with ICI plus CT provided a greater benefit of event-free survival (EFS) (HR 0.59 95%CI 0.51-0.67 p<0.00001) and overall survival (HR 0.66 95%CI 0.53-0.82 p=0.0002)compared to CT alone. ICI plus CT improved EFS regardless of PD-L1 expression, type of platinum CT, or histology. Patients with PD-L1 ≥1% achieved considerably better EFS than those with PD-L1 <1% (HR 0.40 vs 0.76, p<0.0001). Subgroup analysis showed EFS benefit for all stages (IB and II, IIIA, and IIIB). Treatment-related adverse events grades 3 or 4 were seen in 36% of patients in the intervention arm and 32% of the control arm (p=0.05).
Conclusions
Neoadjuvant therapy with anti-PD-1/PD-L1 plus CT provided significantly higher pathologic response, EFS, and OS compared to CT alone for resectable stage II-III NSCLC patients. More mature data from the trials are awaited to confirm these findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
457P - Disparities in receipt of CDK4/6 inhibitors with endocrine therapy as therapy for hormone receptor-positive, HER2-negative metastatic breast cancer in the real-world setting
Presenter: Gretchen Kimmick
Session: Poster session 04
458P - Metastatic breast cancer: How and how often do we communicate? Results from an Italian national survey
Presenter: Camilla Lisanti
Session: Poster session 04
460P - Impact of fulvestrant utilization on prognostic outcome among patients with HR+ve/HER2-ve metastatic breast cancer: Results from a real-world dataset
Presenter: Shaheenah Dawood
Session: Poster session 04
462P - Health outcomes of treatment sequences with eribulin or other single agents’ chemotherapy for treating relapsed metastatic HER2-negative breast cancer
Presenter: Simone Rivolo
Session: Poster session 04
463P - Impact of two waves of Sars-Cov-2 outbreak on the clinical presentation and outcomes of newly referred breast cancer cases at AP-HP: A retrospective multicenter cohort study
Presenter: Sonia Priou
Session: Poster session 04
464P - Developing a prognostic risk stratification model and treatment options for HER2-positive breast cancer brain metastasis
Presenter: JiaXin Chen
Session: Poster session 04
465P - Reporting of older subgroups enrolled to registration breast cancer trials, 2012-2021
Presenter: Colm Mac Eochagain
Session: Poster session 04